Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$8M
- +49.1% YoY · +21.3% QoQ
- EPS (diluted)
- −$0.13
- +48.0% YoY · +18.8% QoQ
Source: XBRL data from the Aldeyra Therapeutics, Inc. (ALDX) Q3 2025 10-Q on SEC EDGAR. USD.
Aldeyra Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue not disclosed; no approved products and no product sales revenue
- Net loss $7.7M vs $15.1M YoY; loss from operations $8.0M vs $16.1M
- R&D expense $5.4M, down 56.3% YoY; reproxalap primary late-stage focus
- Cash, equivalents, and marketable securities $75.3M at September 30, 2025; net loss $27.4M for nine months
- AbbVie option unexercised as of November 5, 2025; operating losses expected for the foreseeable future
Risk Factors
- New FDA transparency policy: prompt publication of future Complete Response Letters, including potential disclosure of proprietary clinical or regulatory information
- Reproxalap regulatory risk: 2025 Complete Response Letter cited baseline-score differences and requested at least one additional adequate, well-controlled study
- Commercialization risk: AbbVie Option non-exercise could leave Aldeyra funding reproxalap development and commercialization independently
- Pipeline risk: ADX-629 clinical development discontinued in September 2025, pending investigator-sponsored Sjögren-Larsson Syndrome testing
- Financial risk: substantial additional financing required to continue development and commercialization programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aldeyra Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.